TY - JOUR
T1 - Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma
T2 - Does the order of sequencing matter?
AU - Calvani, N.
AU - Morelli, F.
AU - Leo, S.
AU - Orlando, L.
AU - Lombardi, L.
AU - Gnoni, A.
AU - Cinefra, M.
AU - Maiello, E.
AU - Lorusso, V.
AU - Cinieri, S.
PY - 2012/9
Y1 - 2012/9
N2 - To investigate the sequential use of two tyrosine-kinase inhibitors (TKI), sorafenib (SOR) and sunitinib (SUN), in advanced renal carcinoma. We retrospectively analyzed the clinical outcome of 33 patients who had experienced progression or unacceptable toxicity after receiving either sorafenib or sunitinib and then switched to the other reciprocal agent. Progression-free survival (PFS) during the first TKI was similar regardless of drug with a median of 6 months in the SOR-SUN group (n = 15) and 7.5 months in the SUN-SOR group (n = 18). Interestingly, PFS during the second TKI was significantly longer in the SOR-SUN group as compared to the SUN-SOR group with median values of 11 and 3 months, respectively (P = 0.0377; HR 0.46; 95% CI: 0.16-0.95). As a consequence, total PFS (sum of PFS on first and second TKI) was significantly longer in the SOR-SUN group than in the SUNSOR group with medians of 20 versus 10 months, respectively (P = 0.0393; HR 0.47; 95% CI: 0.18-0.96). Median wash-out period between the two TKI was 3 weeks in both groups. Differences in baseline characteristics, including histology and line of treatment, were not significant, and toxicity was not increased during the second part of the sequence. Here, we show that responses can be achieved when a second TKI is given soon after a TKI failure in renal cancer with apparent more durable disease control when SOR is followed by SUN.
AB - To investigate the sequential use of two tyrosine-kinase inhibitors (TKI), sorafenib (SOR) and sunitinib (SUN), in advanced renal carcinoma. We retrospectively analyzed the clinical outcome of 33 patients who had experienced progression or unacceptable toxicity after receiving either sorafenib or sunitinib and then switched to the other reciprocal agent. Progression-free survival (PFS) during the first TKI was similar regardless of drug with a median of 6 months in the SOR-SUN group (n = 15) and 7.5 months in the SUN-SOR group (n = 18). Interestingly, PFS during the second TKI was significantly longer in the SOR-SUN group as compared to the SUN-SOR group with median values of 11 and 3 months, respectively (P = 0.0377; HR 0.46; 95% CI: 0.16-0.95). As a consequence, total PFS (sum of PFS on first and second TKI) was significantly longer in the SOR-SUN group than in the SUNSOR group with medians of 20 versus 10 months, respectively (P = 0.0393; HR 0.47; 95% CI: 0.18-0.96). Median wash-out period between the two TKI was 3 weeks in both groups. Differences in baseline characteristics, including histology and line of treatment, were not significant, and toxicity was not increased during the second part of the sequence. Here, we show that responses can be achieved when a second TKI is given soon after a TKI failure in renal cancer with apparent more durable disease control when SOR is followed by SUN.
KW - Angiogenic inhibitors
KW - Renal cell cancer
KW - Sorafenib tosylate
KW - Sunitinib malate
KW - Targeted molecular therapy
UR - http://www.scopus.com/inward/record.url?scp=84872811400&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872811400&partnerID=8YFLogxK
U2 - 10.1007/s12032-011-0048-0
DO - 10.1007/s12032-011-0048-0
M3 - Article
C2 - 21858552
AN - SCOPUS:84872811400
VL - 29
SP - 1908
EP - 1913
JO - Medical Oncology
JF - Medical Oncology
SN - 1357-0560
IS - 3
ER -